Brookfield Asset Management has stabilised in the week after its September 17 results, but the calm masks a quiet rebuild in short positioning that sets up an interesting divergence with the broader alternative-asset complex.
The standout development this week is a modest but clear rise in short interest. Shorts added roughly 1.16 million shares in a single step — short interest jumped 12.4% over the week to 10.5 million shares, or 0.65% of the free float. That is still an unambiguously low absolute level, and the direction matters more than the quantum here: this is the first meaningful build since the late-August stress episode, when availability compressed to below 250% and cost to borrow briefly spiked to 4.2%. The borrow market itself is now doing the opposite — availability has loosened to nearly 700%, well above even the mid-September reading of around 652% cited in the pre-earnings note, and the cost to borrow has more than halved over the week to just 0.51%. That combination — rising short interest alongside very loose borrow conditions — reads as new positioning being added cheaply, not a short squeeze or a funding squeeze in the making. The ORTEX short score sits at 38.4, effectively flat on the week, and ranks in the 44th percentile among peers. Lending-market pressure is not the story here.
Where BAM diverges from its closest peers is more striking. The stock gained 1.6% on the week on the TSX — a decent outcome in isolation, but the US-listed alternatives names went the other direction. BX fell 2.1%, KKR dropped 1.6%, ARES slid 3.4%, TPG lost 3.8%, and CG shed 2.9%. BN, Brookfield's parent, tracked closer to BAM with a 3.1% weekly gain, suggesting the outperformance is at least partly a Brookfield-family dynamic rather than pure BAM-specific re-rating. The earnings reaction — a 2% gain on September 17 — provided a floor, and the stock has held that ground. But BAM is still down 10% over the past month; the recovery is fragile rather than broad-based.
Valuation tells a mixed story. The EV/EBITDA multiple has compressed by roughly 2.6 turns over the past 30 days to 16.5x, and the PE ratio has fallen nearly three points to 22.1x. Those moves reflect the price decline as much as any fundamental re-rating, but they do put the stock on a cheaper footing than a month ago. The dividend factor score ranks in the 92nd percentile — one of the stronger readings in the dataset — which continues to provide a valuation anchor for income-oriented holders. Short-term EPS momentum scores well at the 80th percentile on a 30-day basis, though the 90-day reading drops to the 35th percentile, suggesting the improvement is recent rather than sustained.
Ownership concentration remains the dominant structural feature. Brookfield Corporation holds roughly 74.7% of shares, leaving the publicly traded float relatively thin. Recent insider activity from late August — option exercises followed by open-market sales by executives including Nicholas Goodman and Justin Beber — totalled a net disposal of about $2.2 million over 90 days. The values are not large in the context of total holdings, and the exercise-then-sell pattern is consistent with routine compensation realisation rather than a directional view on the stock. Capital Research added just over 3 million shares as of June 30, and RBC Global Asset Management added 1.3 million, providing some institutional ballast from the buy side.
With no next earnings date on the calendar yet, the focus shifts to whether the post-Q3 short rebuild sustains or reverses, and whether BAM can close any of the gap that opened against its US-listed alternatives peers during a week that was broadly unkind to the sector.
See the live data behind this article on ORTEX.
Open BAM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
